Reuters logo
2 个月前
BRIEF-Seattle Genetics discontinues Phase 3 trial of vadastuximab talirine
2017年6月19日 / 上午10点53分 / 2 个月前

BRIEF-Seattle Genetics discontinues Phase 3 trial of vadastuximab talirine

June 19 (Reuters) - Seattle Genetics Inc:

* Seattle Genetics discontinues Phase 3 cascade trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia

* Seattle Genetics discontinues Phase 3 cascade trial of vadastuximab talirine (SGN-CD33A) in frontline acute myeloid leukemia

* Seattle Genetics Inc - will closely review data and consult with FDA to determine future plans for vadastuximab talirine development program

* Seattle Genetics - data indicated higher rate of deaths, including fatal infections in vadastuximab talirine-containing arm versus control arm of trial

* Says ‍based on available data, safety concerns in this trial do not appear related to hepatotoxicity​

* Seattle Genetics Inc - suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials

* Seattle Genetics - on track to advance enfortumab vedotin into a pivotal trial in metastatic urothelial cancer in H2 2017 under collaboration with Astellas Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below